azanediylbis(ethane-2,1-diyl) distearate | 117354-51-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: azanediylbis(ethane-2,1-diyl) distearate
• 英文别名: Octadecanoic acid 2-(2-octadecanoyloxy-ethylamino)-ethyl ester；2-(2-Octadecanoyloxyethylamino)ethyl octadecanoate；2-(2-octadecanoyloxyethylamino)ethyl octadecanoate
• CAS: 117354-51-5
• 化学式: C₄₀H₇₉NO₄
• 分子量: 638.072
• InChiKey: HYUGXTFBLJCNFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.4
• 重原子数：
  45
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  cellobiono-1,5-lactone 、 azanediylbis(ethane-2,1-diyl) distearate 以 甲醇 为溶剂， 生成 Octadecanoic acid 2-{(2-octadecanoyloxy-ethyl)-[(2S,3S,5S)-2,3,5,6-tetrahydroxy-4-((2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-hexanoyl]-amino}-ethyl ester
  参考文献：
  名称：

  Higashi, Nobuyuki; Takematsu, Minoru; Niwa, Masazo, Chemistry Letters, 1990, # 4, p. 675 - 678

  摘要：

  DOI：
• 作为产物：
  描述：

  硬脂酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 azanediylbis(ethane-2,1-diyl) distearate
  参考文献：
  名称：

  PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF

  摘要：

  The present disclosure relates to PEGylated lipid compounds and pharmaceutically acceptable salts thereof. Such compounds are useful, for example, as constituent parts of lipid nanoparticle (LNP) formulations for delivery of various active agents. The present disclosure further provides LNPs comprising a disclosed compound. Also provided herein are methods of preparing such PEGylated lipid compounds, as well as pharmaceutical compositions comprising an LNP and an active agent; and methods of use thereof.

  公开号：

  WO2024044728A1

文献信息

• Higashi, Nobuyuki; Takematsu, Minoru; Niwa, Masazo, Chemistry Letters, 1990, # 4, p. 675 - 678
  作者：Higashi, Nobuyuki、Takematsu, Minoru、Niwa, Masazo

  DOI：——

  日期：——
• PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF
  申请人：[en]RENAGADE THERAPEUTICS MANAGEMENT INC.

  公开号：WO2024044728A1

  公开（公告）日：2024-02-29

  The present disclosure relates to PEGylated lipid compounds and pharmaceutically acceptable salts thereof. Such compounds are useful, for example, as constituent parts of lipid nanoparticle (LNP) formulations for delivery of various active agents. The present disclosure further provides LNPs comprising a disclosed compound. Also provided herein are methods of preparing such PEGylated lipid compounds, as well as pharmaceutical compositions comprising an LNP and an active agent; and methods of use thereof.